1107627-02-0

Basic information

• Product Name: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole
• Synonyms: 1-Methyl-1H-benzimidazole-5-boronic acid pinacol ester;1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole;1-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]iMidazole;1-Methyl-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-benzo[d]iMidazole
• CAS NO: 1107627-02-0
• Molecular Formula: C₁₄H₁₉BN₂O₂
• Molecular Weight: 258.12386
• Product Categories: 6
• Mol File: 1107627-02-0.mol

Chemical Properties

• Boiling Point: 400.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.11
• Storage Temp.: 2-8°C
• PKA: 5.26±0.10(Predicted)
• CAS DataBase Reference: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole(1107627-02-0)
• EPA Substance Registry System: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole(1107627-02-0)

Safety Data

• Hazardous Substances Data: 1107627-02-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Reactions and Catalytic Processes:
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole is used as a ligand for coordinating with transition metal ions, facilitating various chemical reactions and catalytic processes. Its ability to bind with metal ions enhances the reactivity and selectivity of these processes, making it a valuable tool in the synthesis of complex organic molecules.
Used in Organic Synthesis:
In the field of organic synthesis, 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole is used as a building block or intermediate for the synthesis of various organic compounds. Its unique structure allows for the formation of new chemical bonds and the creation of novel molecular architectures, expanding the scope of organic chemistry.
Used in Pharmaceutical Chemistry:
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole is being studied for its potential applications in pharmaceutical chemistry. Its ability to coordinate with metal ions and its unique structure make it a promising candidate for the development of new drugs and therapeutic agents. Researchers are exploring its potential as a scaffold for the design of novel pharmaceutical compounds with improved efficacy and selectivity.
Used in Industry and Research:
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole has a wide range of potential uses in various industries and research fields. Its versatile properties and ability to participate in a variety of chemical reactions make it a valuable tool for the development of new materials, catalysts, and chemical processes. Its applications span across different sectors, including chemical manufacturing, pharmaceuticals, materials science, and more.

Upstream product

• 53484-15-4 5-bromo-1-methyl-1H-benzo[d]imidazole 
• 73183-34-3 bis(pinacol)diborane 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 53484-26-7 N-methyl-4-bromo-2-nitroaniline 
• 69038-76-2 2-N-methylamino-5-bromoaniline 

Relevant articles and documents

FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method o

1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF

1,8-naphthyridinone compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrazolo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidinyl carboxamide compounds described herein include 2-heterocyclyl-4-alkyl-pyrazolo[1,5-a]pyrirnidine-3-carboxarnide compounds and variants thereof.

SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted quinolines of formula (1) wherein R1 is a linear or branched C1-6-alkyl, wherein R1 may optionally be substituted by R3 which is selected from the group consisting of a three-, four-, five-, six- or seven-membered cycloalkl; a five-, six- or seven-membered, saturated heterocycle comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; and a five- or six-membered heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; wherein R3 may optionally be substituted further substituted as defined in claim 1 and wherein R2 is selected from the group consisting of halogen, phenyl, a five- or six-membered monocyclic heteroaryl comprising one, two or three heteroatoms each independently selected from the group consisting of N, S and O; a bicyclic, nine-, ten- or eleven-membered, either aromatic or non-aromatic, but not fully saturated heterocycle comprising one, two, three or four heteroatoms each independently selected from the group consisting of N, S and O; wherein R2 may optionally be further substituted as defined in claim 1, and their use in the preparation of medicaments for the treatment of disease such as asthma, COPD, allergic rhinitis, allergic dermatitis and rheumatoid arthritis.

Substituted Quinolines and Their Use As Medicaments

Disclosed are substituted quinolines of formula 1 wherein R1 and R2 are defined herein, the processing of making and using the same.

Pyridine Derivative and Medicinal Agent

A main object of the present invention is to provide a novel pyridine derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, which may be

CINNOLINE DERIVATIVES AS AS BTK INHIBITORS

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine

HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention related to novel heterocyclic amide compounds of Formula 1: as disclosed herein or a pharmaceutically accept able salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosedare compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease